Mirati receives approval from UK’s MHRA for NSCLC therapy

The black arrows point to ferrugionous bodies that are located at the periphery of a focus of non-small cell lung carcinoma, NOS. Credit: Yale Rosen from USA / commons.wikimedia.org.



  • Mirati Therapeutics